|
|
|
|
| LEADER |
02569nam a2200337 u 4500 |
| 001 |
EB001839402 |
| 003 |
EBX01000000000000001003391 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Low, Allison
|
| 245 |
0 |
0 |
|a Comparative clinical and economic effectiveness of anti-vascular endothelial growth factor agents
|h Elektronische Ressource
|c principal investigator: Allison Low ; contributing investigators: Devan Kansagara, Michele Freeman, Rochelle Fu, Kavita Bhavsar, Ambar Faridi, Karli Kondo, Robin Paynter
|
| 260 |
|
|
|a Washington, DC
|b Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service
|c 2017, January 2017
|
| 300 |
|
|
|a 1 PDF file (iv, 123 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Veterans Health
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Retinal Diseases / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Angiogenesis Inhibitors / therapeutic use
|
| 653 |
|
|
|a Vascular Endothelial Growth Factors / drug effects
|
| 710 |
2 |
|
|a United States
|b Department of Veterans Affairs
|
| 710 |
2 |
|
|a Portland VA Medical Center
|b Evidence-based Synthesis Program Center
|
| 710 |
2 |
|
|a Quality Enhancement Research Initiative (U.S.)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Evidence-based synthesis program
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK476461
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Visual impairment is a common problem among Veterans and results in significant reduction in quality of life. Diseases commonly responsible for substantial losses in visual acuity include neovascular ("wet") age-related macular degeneration (AMD), diabetic macular edema (DME), and central or branch retinal vein occlusion (CRVO or BRVO). While the etiologies of these diseases are complex, all are driven at least in part by vascular endothelial growth factors (VEGFs). This has led to the development of several drugs called anti-VEGF agents designed to block these factors and thus limit their damage to the eye. The most commonly used anti-VEGF agents--aflibercept, bevacizumab, and ranibizumab--have been shown to slow and even reverse the vision loss typically seen in patients with AMD, DME, BRVO, and CRVO. The comparative effectiveness, harms, and costs of these drugs are unclear
|